Andere Sprachen Kiora Pharmaceuticals, Inc.

Aktien

A3DZ7F

US49721T3095

KPRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.05.2024			% 5 Tage	% 1. Jan.
0,57 ^USD	-1,98 %		+17,24 %	+9,11 %

25.03.	Kiora Pharmaceuticals, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
09.02.	KIORA PHARMACEUTICALS, INC. : HC Wainwright bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Kiora Pharmaceuticals Reports First Quarter Results, Update on Pipeline of Drugs Targeting Retinal Disease	13.05.
Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M	10.05.
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease	10.05.
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference	08.05.
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa	06.05.
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases, Approval Granted to Initiate Clinical Validation Study	12.04.
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study	11.04.
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences	05.04.
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting	28.03.
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases	25.03.
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye	08.03.
Kiora Pharmaceuticals Grants License to Thea Open for Molecular Photoswitch Product - Shares Surge	01.02.
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million	01.02.
Kiora Pharmaceuticals, Inc. announced that it expects to receive $42.274525 million in funding from ADAR1 Capital Management, LLC, Nantahala Capital Management, LLC, Rosalind Advisors, Inc., Stonepine Capital Management LLC, Velan Capital Partners LP	01.02.
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties	31.01.
Kiora Pharmaceuticals, Inc. Enters into an Exclusive License and Development Agreement with Théa Open Innovation SAS	31.01.
Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301	17.11.
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa	09.11.
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Kiora Pharmaceuticals, Inc.

Aktien

A3DZ7F

US49721T3095

KPRX

Andere Sprachen

Filter